LifeMD Slashes Full-Year Outlook as Q3 Revenue Misses Guidance
LFMD is trading near its 52-week low of $1.6 (3.7% below the low).
Summary
LifeMD posted Q3 revenue of $44.6 million, down 7% year-over-year and below its own guidance, and cut full-year 2026 revenue guidance to $188-191 million from $205.5-212.5 million. The EBITDA outlook deteriorated far more: full-year adjusted EBITDA is now guided to a loss of $12.6-10.6 million versus the prior negative $6.0 million to breakeven, and Q4 is guided to a loss of $2-4 million, with Q4 revenue seen at $46 million to $49 million. The quarter's loss per share was 11 cents. Management blamed a deliberate $9.5 million sequential cut in marketing spend and partnerships ramping slower than expected, though it points to cost per acquisition down 32% and adjusted EBITDA improving about $3.1 million sequentially to roughly breakeven. This lands days after the company disclosed it was delaying its Q3 10-Q to correct revenue and expense recognition errors, so the reported numbers carry added scrutiny. Cash stood at $21.9 million with no debt at quarter end, and they closed a $12.5 million senior secured term loan with Avenue Capital afterward to fund working capital for branded GLP-1 fulfillment. The stock is already near its 52-week low, and a guidance reset of this size keeps pressure on the equity.
At the time of this announcement, LFMD was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $1.60 to $5.38. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.